# SeekGene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/seekgene

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.seekgene.com
- Total disclosed funding: $15M
- Latest round: Series A (Jan 8, 2021)
- Investors on record: 3

## About

Established in 2015 and based in Beijing, China, SeekGene is a cell detection technology developer that focuses on the development and application of single-cell sorting detection technology. The company has set up departments in Shanghai, Guangzhou, Chengdu, Wuhan and other places. It hasacquired 11 invention patent applications, 10 authorized software works, and has been recognized as the High-tech enterprises and the Zhongguancun high-tech enterprises. The company has cooperated with LaNova, Peking University People's Hospital, and Peking University First Hospital. In January 2021, SeekGene raised over CNY 100 million in series A funding led by BioTrack Capital.

The company has established the SeekOne high-throughput single-cell library construction platform, the SeekGene Online automated online data analysis platform, and provides products such as test kits, the SeekOne digital droplet analyzer, the SeekSoul Tools analysis software, and the SeekSoul CMDB database. It also provides single-cell full-chain solutions, including sample transportation, library construction and amplification, tissue dissociation, bioinformatics analysis, and cell labeling.

The company generates revenue by providing a full-chain solution in the field of single-cell sequencing.

## Funding rounds

- Series A, Jan 8, 2021, $15M — CD Capital, BioTrack Capital
- Angel, Oct 1, 2018 — ZhenFund

## Investors

- ZhenFund (https://capitalatlas.ai/funds/zhenfund) — Angel
- CD Capital — Series A
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series A